Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02YPU
|
||||
| Former ID |
DNCL002966
|
||||
| Drug Name |
Pyridoxamine
|
||||
| Synonyms |
Pyridorin (TN)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Diabetic kidney disease; Diabetic nephropathy [ICD9: 250.4; ICD10:E11.22, E11.21] | Phase 3 | [524788] | ||
| Company |
Nephrogenex
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C8H12N2O2
|
||||
| Canonical SMILES |
CC1=NC=C(C(=C1O)CN)CO
|
||||
| InChI |
1S/C8H12N2O2/c1-5-8(12)7(2-9)6(4-11)3-10-5/h3,11-12H,2,4,9H2,1H3
|
||||
| InChIKey |
NHZMQXZHNVQTQA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
3816, 831723, 835061, 835065, 835069, 4252720, 4451228, 7890124, 8143574, 8150947, 10319847, 10537035, 11142447, 11406185, 11457881, 11459944, 15194988, 24305802, 24439405, 26651867, 29196271, 29196274, 47217156, 49737755, 50070585, 50071196, 50108077, 50397717, 53776771, 57320699, 57566563, 57641282, 85089056, 85164961, 91056273, 92298009, 103717483, 104296624, 104813139, 118299127, 124635911, 124877191, 125616993, 126524049, 126671835, 127280580, 127280581, 127280582, 127280583, 127329709
|
||||
| ChEBI ID |
ChEBI:16410
|
||||
| Target and Pathway | |||||
| Target(s) | Advanced glycosylation end product-specific receptor | Target Info | Inhibitor | [526411], [530891] | |
| Pathway Interaction Database | amb2 Integrin signaling | ||||
| References | |||||
| Ref 526411 | The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002 Sep;51(9):2826-32. | ||||
| Ref 530891 | Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.